Skip to main content

Table 9 Number of administrations for each product

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent Induction year Maintenance year 5 year total
Adalimumab 27 26 131
Etanercept 64 52 272
Infliximab 8 7 36
Ustekinumab 5 4 22